



## MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent licensee of the Blue Cross and Blue Shield Association

# Medical Policy Focal Treatments for Prostate Cancer

### Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

### Policy Number: 733

BCBSA Reference Number: 8.01.61 (For Plan internal use only)

### Related Policies

- Cryosurgical Ablation of Miscellaneous Solid Tumors Other Than Liver, Prostate, or Dermatologic Tumors, #[260](#)
- Magnetic Resonance Imaging–Guided Focused Ultrasound #[243](#)
- Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer, #[307](#)

### Policy

#### Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Use of any focal therapy modality to treat individuals with localized prostate cancer is **INVESTIGATIONAL**.

### Prior Authorization Information

#### Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

#### Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	This is <b>not</b> a covered service.
Commercial PPO and Indemnity	This is <b>not</b> a covered service.

### CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

*The following codes are included below for informational purposes only; this is not an all-inclusive list.*

**The following HCPCS code is considered investigational for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:**

### CPT Codes

CPT codes:	Code Description
55880	Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance

### Description

#### Prostate Cancer

Prostate cancer is the second most common cancer diagnosed among men in the U.S. According to the National Cancer Institute, nearly 268,490 new cases are estimated to be diagnosed in the U.S. in 2022, associated with around 34,500 deaths.<sup>1</sup> Prostate cancer is more likely to develop in older men and in non-Hispanic Black men. About 6 in 10 cases are diagnosed in men who are  $\geq 65$  years of age, and it is rare in men  $< 40$  years of age. Autopsy studies in the pre-prostate-specific antigen (PSA) screening era identified incidental cancerous foci in 30% of men 50 years of age, with incidence reaching 75% at age 80 years.<sup>2</sup> However, the National Cancer Institute Surveillance Epidemiology and End Results Program data have shown that age-adjusted cancer-specific mortality rates for men with prostate cancer declined from 40 per 100,000 in 1992 to 19 per 100,000 in 2018. This decline has been attributed to a combination of earlier detection via PSA screening and improved therapies.

#### Diagnosis

From a clinical standpoint, different types of localized prostate cancers may appear similar during initial diagnosis.<sup>3</sup> However, prostate cancer often exhibits varying degrees of risk progression that may not be captured by accepted clinical risk categories (eg, D'Amico criteria) or prognostic tools based on clinical findings (eg, PSA titers, Gleason grade, or tumor stage).<sup>4,5,6,7,8</sup> In studies of conservative management, the risk of localized disease progression based on prostate cancer-specific survival rates at 10 years may range from 15%<sup>9,10</sup> to 20%<sup>11</sup>, to perhaps 27% at 20-year follow-up.<sup>12</sup> Among elderly men ( $\geq 70$  years) with this type of low-risk disease, comorbidities typically supervene as a cause of death; these men will die from the comorbidities of prostate cancer rather than from cancer itself. Other very similar-appearing low-risk tumors may progress unexpectedly and rapidly, quickly disseminating and becoming incurable.

#### Treatments

The divergent behavior of localized prostate cancers creates uncertainty about whether to treat immediately.<sup>13,14</sup> A patient may choose definitive treatment up front.<sup>15</sup> Surgery (radical prostatectomy) or external-beam radiotherapy are frequently used to treat patients with localized prostate cancer.<sup>14,16</sup> Complications most commonly reported with radical prostatectomy or external-beam radiotherapy and with the greatest variability are incontinence (0% to 73%) and other genitourinary toxicities (irritative and obstructive symptoms); hematuria (typically  $\leq 5\%$ ); gastrointestinal and bowel toxicity, including nausea and loose stools (25% to 50%); proctopathy, including rectal pain and bleeding (10% to 39%); and erectile dysfunction, including impotence (50% to 90%).<sup>16</sup>

American Urological Association guidelines state that for patients with low-risk prostate cancer, clinicians should recommend active surveillance.<sup>17</sup> With this approach, patients forego immediate therapy but continue regular monitoring until signs or symptoms of disease progression are evident, at which point curative treatment is instituted.<sup>18,19</sup>

## **Focal Treatments for Localized Prostate Cancer**

Given significant uncertainty in predicting the behavior of individual localized prostate cancers, and the substantial adverse events associated with definitive treatments, investigators have sought a therapeutic middle ground. The latter seeks to minimize morbidity associated with radical treatment in those who may not actually require surgery while reducing tumor burden to an extent that reduces the chances for rapid progression to incurability. This approach is termed focal treatment, in that it seeks to remove, using any of several ablative methods described next, cancerous lesions at high-risk of progression, leaving behind uninvolved glandular parenchyma. The overall goal of any focal treatment is to minimize the risk of early tumor progression and preserve erectile, urinary, and rectal functions by reducing damage to the neurovascular bundles, external sphincter, bladder neck, and rectum.<sup>20,21,22,23,24</sup> Although focal treatments are offered as an alternative middle approach to manage localized prostate cancer, several key issues must be considered in choosing it. These include patient selection, lesion selection, therapy monitoring, and modalities used to ablate lesions.

### **Patient Selection**

A proportion of men with localized prostate cancer have been reported to have (or develop) serious misgivings and psychosocial problems in accepting active surveillance, sometimes leading to inappropriately discontinuing it.<sup>25</sup> Thus, the appropriate patient selection is imperative for physicians who must decide whether to recommend active surveillance or focal treatment for patients who refuse radical therapy or for whom it is not recommended due to the risk/benefit balance.<sup>26</sup>

### **Lesion Selection**

Proper lesion selection is a second key consideration in choosing a focal treatment for localized prostate cancer. Although prostate cancer is a multifocal disease, clinical evidence has shown that between 10% and 40% of men who undergo radical prostatectomy for presumed multifocal disease actually have a unilaterally confined discrete lesion, which, when removed, would “cure” the patient.<sup>27,28,29</sup> This view presumably has driven the use of regionally targeted focal treatment variants, such as hemiablation of half the gland containing the tumor, or subtotal prostate ablation via the “hockey stick” method.<sup>30</sup> While these approaches can be curative, the more extensive the treatment, the more likely the functional adverse outcomes would approach those of radical treatments.

The concept that clinically indolent lesions comprise most of the tumor burden in organ-confined prostate cancer led to the development of a lesion-targeted strategy, which is referred to as “focal therapy” in this evidence review.<sup>31</sup> This involves treating only the largest and highest grade cancerous focus (referred to as the “index lesion”), which has been shown in pathologic studies to determine the clinical progression of the disease.<sup>32,33</sup> This concept is supported by molecular genetics evidence that suggests that a single index tumor focus is usually responsible for disease progression and metastasis.<sup>34,35</sup> The index lesion approach leaves in place small foci less than 0.5 cm<sup>3</sup> in volume, with a Gleason score less than 7, that are considered unlikely to progress over a 10- to 20-year period.<sup>36,37,38</sup> This also leaves available subsequent definitive therapies as needed should disease progress.

Identification of prostate cancer lesions (disease localization) particularly the index lesion, is critical to the oncologic success of focal therapy; equally important to success is the ability to guide focal ablation energy to the tumor and assess treatment effectiveness. At present, no single modality reliably meets the requirements for all 3 activities (disease localization, focal ablation energy to the tumor, assessment of treatment effectiveness).<sup>26,31</sup> Systematic transrectal ultrasound-guided biopsy alone has been investigated; however, it has been considered insufficient for patient selection or disease localization for focal therapy.<sup>39,40,41,42,43</sup> See evidence review 7-01-121 policy #307 on saturation biopsy for prostate cancer for additional information.

Multiparametric magnetic resonance imaging (mpMRI), typically including T1-, T2-, diffusion-weighted imaging, and dynamic contrast-enhanced imaging, has been recognized as a promising modality to risk-stratify prostate cancer and select patients and lesions for focal therapy.<sup>25,31,39</sup> Evidence has shown mpMRI can detect high-grade, large prostate cancer foci with performance similar to transperineal prostate mapping using a brachytherapy template.<sup>44</sup> For example, for the primary endpoint definition

(lesion,  $\geq 4$  mm; Gleason score,  $\geq 3+4$ ), with transperineal prostate mapping as the reference standard, sensitivity, negative predictive value, and negative likelihood ratios with mpMRI were 58% to 73%, 84% to 89%, and 0.3 to 0.5, respectively. Specificity, positive predictive value, and positive likelihood ratios were 71% to 84%, 49% to 63%, and 2.0 to 3.44, respectively. The negative predictive value of mpMRI appears sufficient to rule out clinically significant prostate cancer and may have clinical use in this setting. However, although mpMRI technology has the capability to detect and risk-stratify prostate cancer, several issues constrain its widespread use for these purposes (eg, mpMRI requires highly specialized MRI-compatible equipment; biopsy within the magnetic resonance imaging (MRI) scanner is challenging; interpretation of prostate MRI images requires experienced urologists) and it is still necessary to histologically confirm suspicious lesions using transperineal prostate mapping.<sup>45</sup>

### **Therapy Monitoring**

Controversy exists about the proper endpoints for focal therapy of prostate cancer. The primary endpoint of focal ablation of clinically significant disease with negative biopsies evaluated at 12 months posttreatment is generally accepted according to a European consensus report.<sup>39</sup> The clinical validity of an MRI to analyze the presence of residual or recurrent cancer compared with histologic findings is offered as a secondary endpoint. However, MRI findings alone are not considered sufficient in a follow-up.<sup>39</sup> Finally, although investigators have indicated that PSA levels should be monitored, PSA levels are not considered valid endpoints because the utility of PSA kinetics in tissue preservation treatments has not been established.<sup>36</sup>

### **Modalities Used to Ablate Lesions**

Five ablative methods for which clinical evidence is available are considered herein: focal laser ablation; high-intensity focused ultrasound (HIFU); cryoablation; radiofrequency ablation (RFA); and photodynamic therapy.<sup>20,21,23,24,30,31,34,36,39,46,47</sup> Each method requires placement of a needle probe into a tumor volume followed by delivery of some type of energy that destroys the tissue in a controlled manner. All methods except focal laser ablation currently rely on ultrasound guidance to the tumor focus of interest; focal laser ablation uses MRI to guide the probe. This evidence review does not cover focal brachytherapy.

### **Focal Laser Ablation**

Focal laser ablation refers to the destruction of tissue using a focused beam of electromagnetic radiation emitted from a laser fiber introduced transperineally or transrectally into the cancer focus. The tissue is destroyed through the thermal conversion of the focused electromagnetic energy into heat, causing coagulative necrosis. Other terms for focal laser ablation include photothermal therapy, laser interstitial therapy, and laser interstitial photocoagulation.<sup>48</sup>

### **High-Intensity Focused Ultrasound**

High-intensity focused ultrasound focuses high-energy ultrasound waves on a single location, which increases the local tissue temperature to over 80°C. This causes a discrete locus of coagulative necrosis of approximately 3x3x10 mm. The surgeon uses a transrectal probe to plan, perform, and monitor treatment in a real-time sequence to ablate the entire gland or small discrete lesions.

### **Cryoablation**

Cryoablation induces cell death through direct cellular toxicity from disruption of the cell membrane caused by ice-ball crystals and vascular compromise from thrombosis and ischemia secondary to freezing below -30°C. Using a transperineal prostate mapping template, cryoablation is performed by transperineal insertion under transrectal ultrasound guidance of a varying number of cryoprobe needles into the tumor

### **Radiofrequency Ablation**

Radiofrequency ablation uses the energy produced by a 50-watt generator at a frequency of 460 kHz. Energy is transmitted to the tumor focus through 15 needle electrodes inserted transperineally under ultrasound guidance. Radiofrequency ablation produces an increase in tissue temperature causing coagulative necrosis.

## Photodynamic Therapy

Photodynamic therapy uses an intravenous photosensitizing agent, which distributes through prostate tissue, followed by light delivered transperineally by inserted needles. The light induces a photochemical reaction that produces reactive oxygen species that are highly toxic and causes functional and structural tissue damage (ie, cell death). A major concern with photodynamic therapy is that real-time monitoring of tissue effects is not possible, and the variable optical properties of prostate tissue complicate the assessment of necrosis and treatment progress.

## Summary

### Description

Prostate cancer is the second most common cancer diagnosis men receive in the U.S., and the behavior of localized prostate cancer can prove difficult to predict on a case-by-case basis. Most men with prostate cancer undergo whole-gland treatments, which can often lead to substantial adverse events. To reduce tumor burden and minimize morbidity associated with radical treatment, investigators have developed a therapy known as focal treatment. Focal treatment seeks to ablate either an “index” lesion (defined as the largest cancerous lesion with the highest grade tumor), or alternatively, to ablate nonindex lesions and other areas where cancer has been known to occur. Addressed in this review are several ablative methods used to remove cancerous lesions in localized prostate cancer (eg, focal laser ablation, high-intensity focused ultrasound [HIFU], cryoablation, radiofrequency ablation [RFA], photodynamic therapy). All methods, except focal laser ablation, use ultrasound guidance to focus on the tumor (focal laser ablation uses magnetic resonance imaging to guide the probe).

### Summary of Evidence

For individuals who have primary localized prostate cancer who receive focal therapy using laser ablation, HIFU, cryoablation, RFA, or photodynamic therapy, the evidence includes systematic reviews, studies from a registry cohort, and numerous observational studies. Relevant outcomes are overall survival (OS), disease-specific survival, symptoms, change in disease status, functional outcomes, quality of life (QoL), and treatment-related morbidity. The evidence is highly heterogeneous and inconsistently reports clinical outcomes. No prospective, comparative evidence was found for the majority of focal ablation techniques versus current standard treatment of localized prostate cancer, including radical prostatectomy, external-beam radiotherapy, or active surveillance. Methods have not been standardized to determine which and how many identified cancerous lesions should be treated for best outcomes. No evidence supports which, if any, of the focal techniques leads to better functional outcomes. Although high disease-specific survival rates have been reported, the short follow-up periods and small sample sizes preclude conclusions on the effect of any of these techniques on OS rates. The adverse event rates associated with focal therapies appear to be superior to those associated with radical treatments (eg, radical prostatectomy, external-beam radiotherapy); however, the evidence is limited in its quality, reporting, and scope. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## Policy History

Date	Action
11/2022	Annual policy review. Description, summary, and references updated. Minor editorial refinements to policy statements; intent unchanged.
10/2021	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2021	Medicare information removed. See MP #132 Medicare Advantage Management for local coverage determination and national coverage determination reference. Clarified coding information.
11/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
6/2020	Local Coverage Determination (LCD): Salvage High-intensity Focused Ultrasound (HIFU) Treatment in Prostate Cancer (PCa) (L38262) added. Effective 4/1/2020.
10/2019	Annual policy review. Description, summary, and references updated. Policy statements unchanged.

10/2018	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
10/2017	Annual policy review. New references added.
7/2017	Clarified coding information.
10/2016	Annual policy review. New references added.
11/2015	Annual policy review. New references added.
9/2015	New medical policy describing investigational indications. Effective 9/1/2015.

## Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

## References

1. American Cancer Society. Key statistics for prostate cancer. January 12, 2022. <https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html>. Accessed August 1, 2022
2. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early-stage prostate cancer: review of the current literature. *Cancer*. Apr 15 2008; 112(8): 1650-9. PMID 18306379
3. Bangma CH, Roemeling S, Schroder FH. Overdiagnosis and overtreatment of early detected prostate cancer. *World J Urol*. Mar 2007; 25(1): 3-9. PMID 17364211
4. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. *JAMA*. Jun 09 2004; 291(22): 2713-9. PMID 15187052
5. Ploussard G, Epstein JI, Montironi R, et al. The contemporary concept of significant versus insignificant prostate cancer. *Eur Urol*. Aug 2011; 60(2): 291-303. PMID 21601982
6. Harnden P, Naylor B, Shelley MD, et al. The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis. *Cancer*. Mar 01 2008; 112(5): 971-81. PMID 18186496
7. Brimo F, Montironi R, Egevad L, et al. Contemporary grading for prostate cancer: implications for patient care. *Eur Urol*. May 2013; 63(5): 892-901. PMID 23092544
8. Eylert MF, Persad R. Management of prostate cancer. *Br J Hosp Med (Lond)*. Feb 2012; 73(2): 95-9. PMID 22504752
9. Eastham JA, Kattan MW, Fearn P, et al. Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group. *Eur Urol*. Feb 2008; 53(2): 347-54. PMID 17544572
10. Bill-Axelsson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. *N Engl J Med*. May 12 2005; 352(19): 1977-84. PMID 15888698
11. Thompson IM, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. *N Engl J Med*. Aug 15 2013; 369(7): 603-10. PMID 23944298
12. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. *JAMA*. May 04 2005; 293(17): 2095-101. PMID 15870412
13. Borley N, Feneley MR. Prostate cancer: diagnosis and staging. *Asian J Androl*. Jan 2009; 11(1): 74-80. PMID 19050692
14. Freedland SJ. Screening, risk assessment, and the approach to therapy in patients with prostate cancer. *Cancer*. Mar 15 2011; 117(6): 1123-35. PMID 20960523
15. Ip S, Dahabreh IJ, Chung M, et al. An evidence review of active surveillance in men with localized prostate cancer. Evidence Report/Technology Assessment no. 204 (AHRQ Publication No. 12-E003-EF). Rockville, MD: Agency for Research and Quality; 2011.
16. American Urological Association. Guideline for management of clinically localized prostate cancer: 2007 update. Linthicum, MD: American Urological Association Education and Research; 2007.
17. Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. 2022; <https://www.auanet.org/guidelines/guidelines/clinically-localized-prostate-cancer-uaa/astro-guideline-2022>. Accessed August 1, 2022.

18. Whitson JM, Carroll PR. Active surveillance for early-stage prostate cancer: defining the triggers for intervention. *J Clin Oncol.* Jun 10 2010; 28(17): 2807-9. PMID 20439633
19. Albertsen PC. Treatment of localized prostate cancer: when is active surveillance appropriate?. *Nat Rev Clin Oncol.* Jul 2010; 7(7): 394-400. PMID 20440282
20. Jacome-Pita F, Sanchez-Salas R, Barret E, et al. Focal therapy in prostate cancer: the current situation. *Ecancermedicalscience.* 2014; 8: 435. PMID 24944577
21. Nguyen CT, Jones JS. Focal therapy in the management of localized prostate cancer. *BJU Int.* May 2011; 107(9): 1362-8. PMID 21223478
22. Lindner U, Lawrentschuk N, Schatloff O, et al. Evolution from active surveillance to focal therapy in the management of prostate cancer. *Future Oncol.* Jun 2011; 7(6): 775-87. PMID 21675840
23. Iberti CT, Mohamed N, Palese MA. A review of focal therapy techniques in prostate cancer: clinical results for high-intensity focused ultrasound and focal cryoablation. *Rev Urol.* 2011; 13(4): e196-202. PMID 22232569
24. Lecornet E, Ahmed HU, Moore CM, et al. Conceptual basis for focal therapy in prostate cancer. *J Endourol.* May 2010; 24(5): 811-8. PMID 20443699
25. Tay KJ, Mendez M, Moul JW, et al. Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era?. *Curr Opin Urol.* May 2015; 25(3): 185-90. PMID 25768694
26. Passoni NM, Polascik TJ. How to select the right patients for focal therapy of prostate cancer?. *Curr Opin Urol.* May 2014; 24(3): 203-8. PMID 24625428
27. Scales CD, Presti JC, Kane CJ, et al. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database. *J Urol.* Oct 2007; 178(4 Pt 1): 1249-52. PMID 17698131
28. Mouraviev V, Mayes JM, Sun L, et al. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. *Cancer.* Aug 15 2007; 110(4): 906-10. PMID 17587207
29. Mouraviev V, Mayes JM, Madden JF, et al. Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. *Technol Cancer Res Treat.* Apr 2007; 6(2): 91-5. PMID 17375971
30. Muto S, Yoshii T, Saito K, et al. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. *Jpn J Clin Oncol.* Mar 2008; 38(3): 192-9. PMID 18281309
31. Kasivisvanathan V, Emberton M, Ahmed HU. Focal therapy for prostate cancer: rationale and treatment opportunities. *Clin Oncol (R Coll Radiol).* Aug 2013; 25(8): 461-73. PMID 23759249
32. Mouraviev V, Villers A, Bostwick DG, et al. Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. *BJU Int.* Oct 2011; 108(7): 1074-85. PMID 21489116
33. Mouraviev V, Mayes JM, Polascik TJ. Pathologic basis of focal therapy for early-stage prostate cancer. *Nat Rev Urol.* Apr 2009; 6(4): 205-15. PMID 19352395
34. Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. *Nat Med.* May 2009; 15(5): 559-65. PMID 19363497
35. Guo CC, Wang Y, Xiao L, et al. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers. *Hum Pathol.* May 2012; 43(5): 644-9. PMID 21937078
36. Ahmed HU, Emberton M. Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?. *World J Urol.* Oct 2008; 26(5): 457-67. PMID 18704441
37. Stamey TA, Freiha FS, McNeal JE, et al. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. *Cancer.* Feb 01 1993; 71(3 Suppl): 933-8. PMID 7679045
38. Nelson BA, Shappell SB, Chang SS, et al. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. *BJU Int.* Jun 2006; 97(6): 1169-72. PMID 16686706
39. van den Bos W, Muller BG, Ahmed H, et al. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. *Eur Urol.* Jun 2014; 65(6): 1078-83. PMID 24444476
40. Mayes JM, Mouraviev V, Sun L, et al. Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer?. *Urol Oncol.* Mar-Apr 2011; 29(2): 166-70. PMID 19451000

41. Sinnott M, Falzarano SM, Hernandez AV, et al. Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: implications for focal therapy. *Prostate*. Aug 01 2012; 72(11): 1179-86. PMID 22161896
42. Gallina A, Maccagnano C, Suardi N, et al. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy. *BJU Int*. Jul 2012; 110(2 Pt 2): E64-8. PMID 22093108
43. Briganti A, Tutolo M, Suardi N, et al. There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. implications for focal therapies. *Prostate*. Jun 01 2012; 72(8): 925-30. PMID 21965006
44. Arumainayagam N, Ahmed HU, Moore CM, et al. Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. *Radiology*. Sep 2013; 268(3): 761-9. PMID 23564713
45. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. *Eur Urol*. Apr 2011; 59(4): 477-94. PMID 21195536
46. National Institute for Health and Care Excellence (NICE). Prostate cancer: diagnosis and management. [NG131]. 2019; <https://www.nice.org.uk/guidance/ng131/chapter/Recommendations>. Accessed August 3, 2022.
47. National Institute for Health and Care Excellence (NICE). Focal Therapy Using High-Intensity Focused Ultrasound for Localized Prostate Cancer [IPG424]. 2012; <https://www.nice.org.uk/guidance/ipg424>. Remove July 28, 2021.
48. Lee T, Mendhiratta N, Sperling D, et al. Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience. *Rev Urol*. 2014; 16(2): 55-66. PMID 25009445
49. Azzouzi AR, Vincendeau S, Barret E, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. *Lancet Oncol*. Feb 2017; 18(2): 181-191. PMID 28007457
50. Valerio M, Ahmed HU, Emberton M, et al. The role of focal therapy in the management of localised prostate cancer: a systematic review. *Eur Urol*. Oct 2014; 66(4): 732-51. PMID 23769825
51. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol*. Oct 2009; 62(10): e1-34. PMID 19631507
52. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. *Int J Radiat Oncol Biol Phys*. Jul 15 2006; 65(4): 965-74. PMID 16798415
53. Wolff RF, Ryder S, Bossi A, et al. A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. *Eur J Cancer*. Nov 2015; 51(16): 2345-67. PMID 26254809
54. Bates AS, Ayers J, Kostakopoulos N, et al. A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. *Eur Urol Oncol*. Jun 2021; 4(3): 405-423. PMID 33423943
55. Hopstaken JS, Bomers JGR, Sedelaar MJP, et al. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years?. *Eur Urol*. Jan 2022; 81(1): 5-33. PMID 34489140
56. Lepor H, Llukani E, Sperling D, et al. Complications, Recovery, and Early Functional Outcomes and Oncologic Control Following In-bore Focal Laser Ablation of Prostate Cancer. *Eur Urol*. Dec 2015; 68(6): 924-6. PMID 25979568
57. Natarajan S, Raman S, Priester AM, et al. Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial. *J Urol*. Jul 2016; 196(1): 68-75. PMID 26748164
58. Mehralivand S, George AK, Hoang AN, et al. MRI-guided focal laser ablation of prostate cancer: a prospective single-arm, single-center trial with 3 years of follow-up. *Diagn Interv Radiol*. May 2021; 27(3): 394-400. PMID 34003127
59. Chao B, Lepor H. 5-Year Outcomes Following Focal Laser Ablation of Prostate Cancer. *Urology*. Sep 2021; 155: 124-129. PMID 34090887



60. Nahar B, Bhat A, Reis IM, et al. Prospective Evaluation of Focal High Intensity Focused Ultrasound for Localized Prostate Cancer. *J Urol*. Sep 2020; 204(3): 483-489. PMID 32167866
61. Lian H, Zhuang J, Yang R, et al. Focal cryoablation for unilateral low-intermediate-risk prostate cancer: 63-month mean follow-up results of 41 patients. *Int Urol Nephrol*. Jan 2016; 48(1): 85-90. PMID 26531063
62. Mendez MH, Passoni NM, Pow-Sang J, et al. Comparison of Outcomes Between Preoperatively Potent Men Treated with Focal Versus Whole Gland Cryotherapy in a Matched Population. *J Endourol*. Oct 2015; 29(10): 1193-8. PMID 26058496
63. Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. *BJU Int*. Jun 2012; 109(11): 1648-54. PMID 22035200
64. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: prostate cancer. Version 4.2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf). Accessed August 2, 2022.
65. National Cancer Institute. Prostate Cancer Treatment (PDQ)Patient Version: Treatment Option Overview. 2021. [https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq#link/\\_142](https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq#link/_142). Accessed August 2, 2022.
66. U.S. Preventive Services Task Force. Final Recommendation Statement: Prostate Cancer: Screening. 2018; <https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/prostate-cancer-screening1>. Accessed August 2, 2022.